A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice.

ABSTRACT: Opioid use disorders (OUD) and opioid-related fatal overdoses are a public health concern in the United States. Approximately 100,000 fatal opioid-related overdoses occurred annually from mid-2020 to the present, the majority of which involved fentanyl or fentanyl analogs. Vaccines have been proposed as a therapeutic and prophylactic strategy to offer selective and long-lasting protection against accidental or deliberate exposure to fentanyl and closely related analogs. To support the development of a clinically viable anti-opioid vaccine suitable for human use, the incorporation of adjuvants will be required to elicit high titers of high-affinity circulating antibodies specific to the target opioid. Here we demonstrate that the addition of a synthetic TLR7/8 agonist, INI-4001, but not a synthetic TLR4 agonist, INI-2002, to a candidate conjugate vaccine consisting of a fentanyl-based hapten, F₁, conjugated to the diphtheria cross-reactive material (CRM), significantly increased generation of high-affinity F₁-specific antibody concentrations, and reduced drug distribution to the brain after fentanyl administration in mice.

SUBMITTER: Miller SM 

PROVIDER: S-EPMC10333387 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature